Advancing nuclear medicine through innovation

Advancing Nuclear Medicine Through Innovation

Volumn , Issue , 2007, Pages 1-159

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85024112774     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.17226/11985     Document Type: Book

References (146)

1. ACR (American College of Radiology). 2007. Procedures per Medicare fee-for-service by imaging modality. Available from ACR Research Department.
2. ACRIN (American College of Radiology Imaging Network). 2007. Available at http://www. acrin.org/. Accessed February 7, 2007.
3. Adelstein, S. J., A. Kassis, L. Bodei, and G. Mariani. 2003. Radiotoxicity of iodine-125 and other Auger-electron-emitting radionuclides: Background to therapy. Cancer Biother Radiopharm 18:301-316.
4. Akabani, G., S. Carlin, P. Welch, and M. R. Zalutsky. 2006. In vitro cytotoxicity of 211At- labeled trastuzumab in human breast cancer cell lines: Effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl Med Biol 33:333-347.
5. Alexander, G. E., K. Chen, P. Pietrini, S. I., Rapoport, and E. M. Reiman. 2002. Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 159:738-745.
6. AMA (American Medical Association). 2006. Report 2 of the Council on Science and Public Health (A-06) Full Text: Ionizing Radiation Exposure in the Medical Setting. Available at http://www.ama-assn.org/ama/pub/category/print/16406.html. Accessed July 18, 2007.
7. American Chemical Society. 2006. 21st Century Radiochemistry Opportunities: a Symposium Highlighting Nuclear Science Workforce Needs. Atlanta, GA.
8. Amis, E. S., Jr., P. F. Butler, K. E. Applegate, S. B. Birnbaum, L. F. Brateman, J. M. Hevezi, F. A. Mettler, R. L. Morin, M. J. Pentecost, G. G. Smith, K. J. Strauss, and R. K. Zeman. 2007. American College of Radiology white paper on radiation dose in medicine. J Am Coll Radiol 4:272-284.
9. Antunes, P., M. Ginj, H. Zhang, B. Waser, R. P. Baum, J. C. Reubi, and H. Maecke. 2007. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol 34:983-993.
10. ARRT (The American Registry of Radiologic Technologists). 2005. Nuclear medicine technology didactic and clinical competency requirements. Available at http://www.arrt.org/education/ CompReqs/NMT_CX_2005.pdf. Accessed March 29, 2007.
11. Badawi, R. 1999. Introduction to PET physics. Available at http://depts.washington.edu/nucmed/ IRL/pet_intro/toc.html. Accessed on February 8, 2007.
12. Bergen, A. W., and N. E. Caporaso. 1999. Cigarette smoking. J Natl Cancer Institute 91: 1365-1375.
13. Bernard, J., and L. W. Hu. 2000. University research reactors: Issues and challenges. Nuclear Tech 131:379-384.
14. Boyd, M., S. C. Ross, J. Dorrens, N. E. Fullerton, K. W. Tan, M. R. Zalutsky, and R. J. Mairs. 2006. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with a-, ß-, and auger electron-emitting radionuclides. J Nucl Med 47:1007-1015.
15. Brooks, D. J. 2007. Imaging non-dopaminergic function in Parkinson's disease. Mol Imaging Biol 9:217-222.
16. CAMPEP (Commission on Accreditation of Medical Physics Education Programs, Inc.). 2007. CAMPEP Accredited Graduate Programs in Medical Physics. Available at http://www. campep.org/campeplst.grad.asp. Accessed on May 8, 2007.
17. Cantana, C., Y. Wu, M. S. Judenhofer, J. Qi, B. J. Pichler, and S. R. Cherry. 2006. Simultaneous acquisition of multislice PET and MR images: Initial results with a MR-compatible PET scanner. J Nucl Med 47:1968-1976.
18. CDC (Centers for Disease Control and Prevention). 2006. Breast Cancer: Fast Facts. Available at http://www.cdc.gov/cancer/breast/basic_info/facts.htm. Accessed on July 26, 2007.
19. Center for Health Workforce Studies. 2006. Characteristic and Attitudes of Nuclear Medicine Scientists: Findings and Recommendations Based on a 2006 Survey.
20. Chen, P., J. Wang, K. Hope, L. Jin, J. Dick, R. Cameron, J. Brandwein, M. Minden, and R. M. Reilly. 2006. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. J Nucl Med 47: 827-836.
21. Chen, W., T. Cloughesy, N. Kamdar, N. Satyamurthy, M. Bergsneider, L. Liau, P. Mischel, J. Czernin, M. E. Phelps, and D. H. Silverman. 2005. Imaging proliferation in brain tumors with 18F-FLT-PET: Comparison with 18F-FDG. J Nucl Med 46:945-952.
22. Chen, W., D.H. Silverman, S. Delaloye, J. Czernin, N. Kamdar, W. Pope, N. Satyamurthy, C. Schiepers, and T. Cloughesy. 2006. 18F-FDOPA PET imaging of brain tumors: Comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 47:904-911.
23. Cherry, S. R. 2006. The 2006 Henry N. Wagner Lecture: Of mice and men (and positrons)- advances in PET imaging technology. J Nucl Med 47:1735-1745.
24. Collins, J. M., and R. L. Wahl. 2002. PET and drug R&D. Principles and Practice of Positron Emisssion Tomography. Philadelphia: Lippincott Williams & Wilkins.
25. Couturier, O., S. Supiot, M. Degraef-Mougin, A. Faivre-Chauvet, T. Carlier, J. F. Chatal, F. Davodeau, and M. Cherel. 2005. Cancer radioimmunotherapy with alpha-emitting nuclides. Nucl Med Mol Imaging 32:601-614.
26. Davies, A. J., A. Z., Rohatiner, S. Howell, K. E. Britton, S. E. Owens, I. N. Micallef, D. P. Deakin, B. M. Carrington, J. A. Lawrence, S. Vinniecombe, S. J. Mather, J. Clayton, R. Foley, H. Jan, S. Kroll, M. Harris, J. Amess, A. J. Norton, T. A. Lister, and J. A. Radford. 2004. Tositumomab and iodine I-131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 22:1469-1479.
27. Davila-Roman, V. G., G. Vedala, P. Herrero, L. de las Fuentes, J. G. Rogers, D. P. Kelly, and R. J. Gropler. 2002. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 40:271-277.
28. DeLuca, P. 2004. Education and Training for Medical Physicists: an Emergent Career Opportunity. NCI & NIBIB Young Investigator Workshop.
29. DeNardo, S. J. 2005. Radioimmunodetection and therapy of breast cancer. Review. Semin Nuc Med 35:143-151.
30. DHHS (Department of Health and Human Services). 2003. General overview of standard for privacy of individually identifiable health information. Available at http://www.hhs. gov/ocr/hipaa/guidelines/overview.pdf. Accessed March 30, 2007.
31. DiMasi, J. A., R. W. Hansen, and H. G. Grabowski. 2003. The price of innovation: New estimates of drug development costs. J Health Econ 22:151-185.
32. Dobert, N., M. Britten, B. Assmus, U. Berner, C. Menzel, R. Lehmann, N. Hamscho, V. Schachinger, S. Dimmel, A. M. Zeiher, and F. Grunwal. 2004. Transplantation of progenitor cells after reperfused acute myocardial infarction: Evaluation of perfusion and myocardial viability with FDG-PET and thallium SPECT. Eur J Nucl Med Mol Imaging 31:1146-1151.
33. DOE (U.S. Department of Energy). 2001. Vital Legacy of BER Medical Sciences 50-Year Commitment to Improved Healthcare through Nuclear Medicine. Available at http:// doemedicalsciences.org/pubs/sc0033/vitals.html. Accessed on January 31, 2007.
34. DOE (U.S. Department of Energy). 2002. DOE Workshop: Radiochemistry Research Resources. Medical Sciences Division, Biological and Environmental Research, Office of Science, U.S. Department of Energy, Chicago.
35. DOE (U.S. Department of Energy). 2004. Radiopharmaceutical Development and the Office of Science. Report prepared by a Subcommittee of the BERAC. Available at http://www. er.doe.gov/OBER/berac/Reports.html. Accessed on February 8, 2007.
36. DOE (U.S. Department of Energy). 2005. Audit Report: Management of the Department's Isotope Program. DOE/IG-0709. Washington, DC: DOE.
37. DOE (U.S. Department of Energy). 2006. The Programs of the Office of Science. Available at http://www.science.doe.gov/grants/progdesc.html. Accessed on January 31, 2007.
38. DOE (U.S. Department of Energy). 2007a. ACHRE Report: The Atomic Energy Commission and Postwar BioMedical Radiation Research. Available at http://www.so.doe.gov/ HealthSafety/ohre/roadmap/achre/intro_4.html. Accessed on August 6, 2007.
39. DOE (U.S. Department of Energy). 2007b. Office of Biological & Environmental Research: Medical Services Division. Available at http://www.science.doe.gov/ober/msd_top.html. Accessed on February 8, 2007.
40. Du, Y., J. Honeychurch, M. S. Cragg, M. Bayne, M. J. Glennie, P. W. Johnson, and T. M. Illidge. 2004. Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood 103:1485-1494.
41. Dunphy, M. P., A. Freidman, S. M. Larson, and H. W. Strauss. 2005. Association of vascular 18F-FDG uptake with vascular calcification. J Nucl Med 46:1278-84.
42. Eckelman, W. C. 2003.The use of PET and knockout mice in the drug discovery process. Drug Discovery Today 8:404-410.
43. Eckelman, W. C., and P. Richards. 1970. Instant 99m-Tc-DTPA. J Nucl Med 11:761.
44. Eckelman, W. C., and P. Richards. 1971. Instant 99m-Tc compounds. J Nucl Med 10:245-251.
45. Engler, H., A. Forsberg, O. Almkvist, G. Blomquist, E. Larsson, I. Savitcheva, A. Wall, A. Ringheim, B. Langstrom, and A. Nordberg. 2006. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129:2856-2866.
46. Enns, L., K. T. Bogen, J. Wizniak, A. D. Murtha, and M. Meinfeld. 2004. Low-dose radiation hypersensitivity is associated with p53-dependent apoptosis. Mol Cancer Res 2:557-566.
47. Erondu, N., I. Gantz, B. Musser, S. Survawanshi, M. Mallick, C. Addy, J. Cote, G. Bray, K. Fujioka, H. Bays, P. Hollander, S. M. Sanabrai-Bohorquez, W. Eng, B. Langstrom, R. J. Hargreaves, H. D. Burns, A. Kanatani, T. Fukami, D. J. MacNeil, K. M. Gottesdiener, J. M. Amatruda, K. D. Kaufman, and S. B. Heymsfield. 2006. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 4: 275-282.
48. FDA (U.S. Food and Drug Administration). 2005. Guidance for Industry INDS: Approaches to Complying with CGMP During Phase I. Available at www.fda.gov/cber/gdlns/indcgmp. htm. Accessed on May 10, 2007.
49. FDA (U.S. Food and Drug Administration). 2006a. Guidance for Industry, Investigation, and Reviewers Exploratory IND Studies. Available at http://www.fda.gov/CDER/guidance/ 7086fnl.pdf. Accessed on February 8, 2007.
50. FDA (U.S. Food and Drug Administration). 2006b. Memorandum of Understanding between the FDA and the National Cancer Institute and the Centers for Medicaid and Medicare Services. MOU No. 225-06-8001.
51. FDA (U.S. Food and Drug Administration). 2007. Listing of Approved Oncology Drugs with Approved Indications. Available at http://www.fda.gov/cder/cancer/druglistframe.htm. Accessed on February 8, 2007.
52. Fowler, J. S., and T. Ido. 2002. Initial and subsequent approach for the synthesis of 18F-FDG. Semin Nuc Med 32:6-12.
53. Fowler, J. S., Y. S. Ding, and N. D. Volkow. 2003. Radiotracers for positron emission tomography. Seminars in Nuclear Medicine 33:14-27.
54. Garber, K. 2004. Energy boost: The Warburg effect returns in a new theory of cancer. J Natl Cancer Institute 96:1805-1806.
55. Gokhale, A. S., J. Mayadev, B. Pohlman, and R. M. Macklis. 2005. Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti- CD20 radioimmunotherapy. Int J Radiat Oncol Biol Phys 63:194-201.
56. Goldenberg, D. M., R. M. Sharkey, G. Paganelli, J. Barbet, and J. F. Chatal. 2006. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 24:823-834.
57. Herceptin. 2007. HER2 positive metastatic breast cancer treatment. Available at http://www. herceptin.com/herceptin. Accessed June 18, 2007.
58. IAEA (International Atomic Energy Agency). 2002. Assessment of the Teaching and Applications in Radiochemistry.
59. IOM (Institute of Medicine). 1995. Isotopes for Medicine and the Life Sciences, S. J. Adelstein and J. F. Manning, eds. Washington, DC: National Academy Press.
60. Juweid, M. E. and B. D. Cheson. 2006. Positron emission tomography and assessment of cancer therapy. N Engl J Med 354:496-507.
61. Karp, J. S. 2006. Time-of-flight PET. PET Center of Excellence Newsletter.
62. Kates, A. M., P. Herrero, C. Dence, P. Soto, M. Srinivasan, D. G. Delano, A. Ahsani, and R. J. Gropler. 2003. Impact of aging on substrate metabolism by the human heart. J Am Coll Cardiol 41:293-299.
63. Kelloff, G. J., J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, L. Shankar, S. M. Larson, C. C. Sigman, R. L. Schilsky, and D. C. Sullivan. 2005. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11:2785-2808.
64. Ketchum, L. E., M. A. Green, and S. S. Jurisson. 1997. Research radionuclide availability in North America. J. Nucl Med 38:15N-19N.
65. Klunk, W. E., H. Engler, A. Nordberg , Y. Wang, G. Blomqvist, D. P. Holt, M. Bergstrom, I. Savitcheva, G. F. Huand, S. Estrada, B. Ausen, M. L. Debnath, J. Barletta, J. C. Price, J. Sandell, B. J. Lopresti, A. Wall, P. Koivisto, G. Antoni, C. A. Mathis, and B. Langstrom. 2004. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306-319.
66. Koob, G. F. 2006. The neurobiology of addiction: a neuroadaptational view relevant to diagnosis. Addiction 101(Suppl 1):23-30.
67. Koppe, M. J., T. Hendriks, O. C. Boerman, W. J. G. Oyen, and R. P. Bleichrodt. 2006. Radioimmunotherpay is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis. J Nucl Med 47:1867-1874.
68. Kung, H. F., M. P. Kung, and S. R. Choi. 2003. Radiopharmaceuticals for single photon emission computed tomography brain imaging. Semin Nucl Med 33:2-13.
69. Kwekkeboom, D. J., J. Mueller-Brand, G. Paganelli, L. B. Anthony, S. Pauwels, L. K. Kvols, T. M. O'Dorisio, R. Valkema, L. Bodei, M. Chinol, H. R. Maecke, and E. P. Krenning. 2005. Overview of results of peptide receptor radionuclide therapy with three radiolabeled somatostatin analogs. J Nucl Med 46:62S-66S.
70. Lardinois, D., W. Weder, T. F. Hany, E. M. Kamel, S. Korom, B. Seifert, G. K. von Schulthess, and H. C. Steinhert. 2003. Staging of non-small-cell lung cancer with integrated positron emission tomography and computed tomography. N Engl J Med 348:2500-2507.
71. Lee, C. C., G. Sui, A. Elizarov, C. J. Shu, Y. S. Shin, A. N. Dooley, J. Huang, A. Daridon, P. Wyatt, D. Stout, H. C. Kolb, O. N. Witte, N. Satyamurthy, J. R. Heath, M. E. Phelps, S. R. Quake, and H. R. Tseng. 2005. Multistep synthesis of a radiolabeled imaging probe using integrated microfluidics. Science 310:1793-1796.
72. Leyton, J., J. R. Latigo, M. Perumal, H. Dhaliwal, Q. He, and E. O. Aboagye. 2005. Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: The effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 65:4202-4210.
73. Liersch, T., J. Meller, B. Kulle, T. M. Behr, P. Markus, C. Langer, B. M. Ghadimi, W. A. Wegener, J. Kovacs, I. D. Horak, H. Becker, and D. M. Goldenberg. 2005. Phase II trial of carcinoembroynic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: 5-year safety and efficacy results. J Clin Oncol 23:6763-6770.
74. Macklis, R. M. 2004. How and why does radioimmunotherapy work? Int J Radiat Oncol Biol Phys 59:1269-1271.
75. Madsen M. T., J. A. Anderson, J. R. Halama, J. Kleck, D. J. Simpkin, J. R. Votaw, R. E. Wendt, L. E. Williams, and M. V. Yester. 2006. AAPM Task Group 108: PET and PET/CT shielding requirements. Med Phys 33:4-15.
76. Mairs, R. J., S. H. Cunningham, M. Boyd, and S. Carlin. 2000. Applications of gene transfer to targeted radiotherapy. Current Pharm Design 14:1419-1432.
77. Matthay, K. K., J. C. Tan, J. G. Villablanca, G. A. Yanik, J. Veatch, B. Franc, E. Twomey, B. Horn, C. P. Reynolds, S. Groshen, R. C. Seeger, and J. M. Maris. 2006. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: New approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 24:500-506.
78. Mothersill, C., and C. B. Seymour. 2004. Radiation-induced bystander effects-implications for cancer. Nature Reviews Cancer 4:158-164.
79. Mottram, J.C. 1936. Factor of importance in radiosensitivity of tumors. Br J Radio 9:606.
80. Mullin, R. 2003. Drug development costs about $1.7 billion. Chem Eng News 81:8
81. Myers, R., and S. Hume. 2002. Small animal PET. Eur Neuropsychopharmacol 12:545-555.
82. Namdar, M., T. F. Hany, P. Koepfli, P. T. Siegrist, C. Burger, C. A. Wyss, T. F. Luscher, G. K. von Schulthess, and P. A. Kaufmann. 2005. Integrated PET/CT for the assessment of coronary artery disease: A feasible study. J Nucl Med. 46:930-935
83. Nariai T., Y. Tanaka, H. Wakimoto, M. Aoyagi, M. Tamaki, K. Ishiwata, M. Senda, K. Ishii, K. Hirakawa, and K. Ohno. 2005. Usefulness of L-[methyl-11C]methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 103:498-507.
84. NCI (National Cancer Institute). 2005. Understand Cancer Series: Molecular Diagnostics. Available at http://www.cancer.gov/cancertopics/understandingcancer/moleculardiagnostics. Accessed February 8, 2007.
85. NCI (National Cancer Institute). 2007a. The Cancer Genome Atlas Project website. Available at http://cgap.nci.nih.gov/. Accessed on February 8, 2007.
86. NCI (National Cancer Institute). 2007b. Cancer Imaging Program. Available at http://imaging. cancer.gov/programsandresources/specializedinitiatives/dcide. Accessed on February 8, 2007.
87. NCRP (National Council on Radiation Protection and Measurements). 1991. Commentary No. 7: Misadministration of radioactive material in medicine-scientific background.
88. NCRP (National Council on Radiation Protection and Measurements). 2007. 43rd Annual Meeting-Advances in Radiation Protection in Medicine.
89. NIA (National Institute on Aging). July 2006. Fact Sheet. NIH Publication No. 06-3431. Available at http://www.alzheimers.nia.nih.gov. Accessed on February 8, 2007.
90. Nicolini, M., and U. Mazzi. 1999. Editorial. Technetium, rhenium and other metals in chemistry and nuclear medicine, Padova, Italy.
91. NIH (National Institutes of Health). 2002. Title 42. The Public Health Service National Research Institutes Awards and Training. Available at http://grants1.nih.gov/training/ NRSA_NameChangeLegislation.rtf. Accessed on May 8, 2007.
92. NIH (National Institutes of Health). 2006. Information on Clinical Trials and Human Research Studies. Available at http://www.ClinicalTrials.gov. Accessed on February 8, 2007.
93. Nilsson, S., R.H. Larsen, S.D. Foss, L. Balteskard, K.W. Borch, J.E. Westlin, G. Salberg, and Y.S. Bruland. 2005. First clinical experience with a-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 11:4451-4459.
94. NIMH (National Institute of Mental Health). 2006. Obesity Linked with Mood and Anxiety Disorders. Available at http://www.nimh.nig.gov/press/obesity_mooddisorders.cfm. Accessed on February 8, 2007.
95. NLM (National Library of Medicine). 1998. HSTAT Health Services/Technology Assessment Text: Cost of PET. Available at http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat6. section.2250. Accessed on February 8, 2007.
96. NINDS (National Institute of Neurological Disorders and Stroke). 2006a. Frontotemporal Dementia Information Page. Available at http://www.ninds.nih.gov/disorders/picks/picks. htm?css=print. Accessed on February 8, 2007.
97. NINDS (National Institute of Neurological Disorders and Stroke). 2006b. Huntington Disease. Available at http://www.ninds.nih.gov/disorders/huntington/huntington.htm. Accessed on January 8, 2007.
98. NNI (National Nanotechnology Initiative). 2007. Applications/Products. Available at http:// www.nano.gov/html/facts/appsprod.html. Accessed on February 8, 2007.
99. NRC (National Research Council). 1982. Separated Isotopes: Vital Tools for Science & Medicine. Washington, DC: National Academy Press.
100. NRC (National Research Council). 2006. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. National Research Council. Washington, DC: The National Academies Press.
101. NRC (National Research Council). 2007. Benchmarking the Research Competitiveness of the United States in Chemistry. Washington, DC: The National Academies Press.
102. Nuclear Energy Agency. 2000. Beneficial Uses and Production of Isotopes, 2000 update.
103. Nunn, A. D. 2006. The cost of developing imaging agents for routine clinical use. Investigative Radiol 41:206-212.
104. O'Donoghue, J. A., G. Sgouros, C. R. Divgi, and J. L. Humm. 2000. Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry. J Nucl Med 41:538-547.
105. O'Shaughnessy, J. A. 2006. Molecular signatures predict outcomes of breast cancer. N Engl J Med 355:615-617.
106. Palmer, S.E. 1999. Vision Science: Photons to Phenomenology. Cambridge, MA: MIT Press.
107. Phelps, Michael. 2006. Presentation to the Committee on State of Science of Nuclear Medicine, San Francisco, CA. November 15.
108. PHRMA. 2006. 2006 Report: Medicines in development for cancer. Available at http:// newmeds.phrma.org/. Accessed on February 8, 2007.
109. Piccart-Gebhard, M. J., M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, D. Cameron, M. Dowsett, C. H. Barrios, G. Steger, C. S. Huang, M. Andersson, M. Inbar, M. Lichinitser, I. Lang, U. Nitz, H. Iwata, C. Thomssen, C. Lohrisch, T. M. Suter, J. Ruschoff, T. Suto, V. Greatorex, C. Ward, C. Straehle, E. McFadden, M. S. Dolci, R. D., Gelber, and Herceptin Adjuvant (HERA) Trial Study Team. 2005. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672.
110. Piccini, P., and A. Whone. 2004. Functional brain imaging in the differential diagnosis of Parkinson's disease. Lancet Neurol 3:284-290.
111. Pirotte, B., S. Goldman, N. Massager, P. David, D. Wikler, A. Vandesteene, I. Salmon, J. Brotchi, and M. Levivier. 2004. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 45:1293-1298.
112. Pohlman, B. L., J. W. Sweetenham, and R. M. Macklis. 2006. Review of clinical radioimmunotherapy. Expert Rev Anticancer Ther 6: 445-461.
113. Press, O. W. 2003. Radioimmunotherapy for non-Hodgkin's lymphomas: A historical perspective. Semin Oncol 30(2 Suppl 4):10-21.
114. Rajendran J. G., K. R. Hendrickson, A. M. Spence, M. Muzi, K. A. Krohn, and D. A. Mankoff. 2006. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging. 33:44-53.
115. Reardon, D. A., G. Akabani, R. E. Coleman, A. H. Friedman, H. S. Friedman, J. E. Herndon, R. E. McLendon, C. N. Pegram, J. M. Provenzale, J. A. Quinn, J. N. Rich, J. Vredenburgh, A. Desjardins, S. Guruangan, M. Badruddoja, J. Dowell, T. Z. Wong, X. G. Zhao, M. R. Zalutsky, and D. D. Bigner. 2006. Salvage radioimmunotherapy with murine 131Ilabeled anti-tenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results. J Clin Oncol 24:115-122.
116. Reba, R. C., R. W. Atcher, R. G. Bennett, R. D. Finn, L. C. Knight, H. H. Kramer, S. Mtingwa, T. J. Ruth, D. C. Sullivan, and J. B. Woodward. 2000. Final Report. NERAC Subcommittee for Isotope Research & Production Planning, pp 1-32. Available at http://www. nuclear.gov/nerac/finalisotopereport.pdf. Accessed on February 8, 2007.
117. Rivarda, M. J., L. M. Bobekb, R. A. Butlerc, M. A. Garlandd, D. J. Hille, J. K. Kriegerf, J. B. Muckerheideg, B. D. Pattone, and E. B. Silberstein. 2005. The U.S. national isotope program: Current status and strategy for future success. Appl Radiat Isot 63:157-178.
118. Rogers, K. C. 2002. The past and future of university research reactors. Science 295: 2217-2218.
119. Schoenhagen, P., S. S. Halliburton, A. E. Stillman, S. A. Kuzmiak, S. E. Nissen, E. M. Tuzcu, and R. D. White. 2004. Noninvasive imaging of coronary arteries: Current and future role of multi-detector row CT. Radiology 232:7-17.
120. Sequist, L. V., D. W. Bell, T. J. Lynch, and D. A. Haber. 2007. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25:587-595.
121. Sharkey, R. M., and D. M. Goldenberg. 2005. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 46:115S-127S.
122. Shields, A. F. 2006. Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology. Mol Imaging Biol 8:141-150.
123. Shields, A. F. 2006. Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology. Mol Imaging Biol 8:141-150.
124. Shields, A. F., J. R. Grierson, B. M. Dohmen, H. J. Machulla, J. C. Stayanoff, J. M. Lawhorn- Crews, J. E. Obradovich, O. Muzik, and T. J. Managner. 1998. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334-1336.
125. Silverman, D. H., G. W. Small, C. Y. Chang, C. S. Lu, M. A. Kung de Aburto, W. Chen, J. Czernin, S. I. Rapoport, P. Pietrini, G. E. Alexander, M. B. Schapiro, W. J. Jagust, J. M. Hoffman, K. A. Welsh-Bohmer, A. Alavi, C. M. Clark, E. Salmon, M. J. de Leon, R. Mielke, J. L. Cummings, A. P. Kowell, S. S. Gambhir, C. K. Hoh, and M. E. Phelps. 2001. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 286:2120-2127.
126. Spicer, K. M., S. Baron, G. D. Frey, H. O'Brien, R. C. Gostic, R. W. Rowe, and R. M. N. Spellman, eds. 1998. Proceedings of the Medical Isotope Workshop, University of South Carolina, Charleston, SC.
127. Small, G. W., L. M. Ercoli, D. H. Silverman, S. C. Huang, S. Komo, S. Y. Bookheimer, H. Lavretsky, K. Miller, P. Siddarth, N. L. Rasgon, J. C. Mazziotta, S. Saxena, H. M. Wu, M. S. Mega, J. L. Cummings, A. M. Saunders, M. A. Pericak-Vance, A. D. Roses, J. R. Barrio, and M. E. Phelps. 2006. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 97:6037-6042.
128. SNM (Society of Nuclear Medicine). 2005. National Radionuclide Production Enhancement (NRPE) Program: Meeting Our Nation's Need for Radionuclides.
129. Stanford Linear Accelerator Center. 2006. Accelerator Form and Function. Available at http:// www2.slac.stanford.edu/vvc/accelerator.html. Accessed on July 6, 2007.
130. Taharan, N., H. Kai, M. Ishibashi, H. Nakaura, H. Kaida, K. Baba, N. Hayabuchi, and T. Imaizumi. 2006. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 48:1825-1831.
131. Tang, H. R., A. J. Da Silva, K. K. Matthay, D. C. Price, J. P. Huberty, R. A. Hawkins, and B. H. Hasegawa. 2001.Neuroblastoma imaging using a combined CT scanner-scintillation camera and 131I-MIBG. J Nucl Med. 42:237-247.
132. Tawakol, A., R. Q. Migrino, G. G. Bashian, S. Bedri, D. Vermylen, R. C. Cury, D. Yates, G. M. LaMuraglia, K. Furie, S. Houser, H. Gewirtz, J. E. Muller, T. J. Brady, and A. J. Fischman. 2006. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 48:1818-1824.
133. Tillisch, J., R. Brunken, R. Marshall, M. Schwaiger, M. Mandelkern, M. Phelps, and H. Schelbert. 1986. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 314:884-888.
134. Udelson J. E. and E. J. Spiegler. 2001. Emergency department perfusion imaging for suspected coronary artery disease: The ERASE Chest Pain Trial. Md Med Spring (Suppl):90-94.
135. University of Arkansas. For Medical Sciences Radiopharmacuetical List and Package Inserts. Available at http://nuclearpharmacy.uams.edu/resources/PackageInserts.asp. Accessed on May 7, 2007.
136. Wagner, H. N., R. C. Reba, R. Brown, E. Coleman, L. Knight, D. Sullivan, R. Caretta, J. W. Babich, A. Carpenter, D. Nichols, K. Spicer, S. Scott, and T. Tenforde. 1999. Expert Panel Forecast of Future Demand for Medical Isotopes. Available at http://www.ne.doe. gov/nerac/isotopedemand.pdf. Accessed on February 8, 2007.
137. Webber, W. A. 2005. PET for response assessment in oncology: radiotherapy and chemotherapy. Newsline. J Nucl Med 28(Suppl):42-49.
138. Weber, W. A., and H. Wieder. 2006. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging 33: 27-37.
139. Weissleder, R. 2006. Molecular Imaging in Cancer. Science 312:1168-1171.
140. Wieder, H. A., A. J. Beer, K. Lordick, K. Ott, M. Fischer, E.J. Rummeny, S. Ziegler, J.R. Siewer, M. Schwaiger, and W.A. Weber. 2005. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 46:2029-2034.
141. Wierenga, D. E., and C. R. Eaton. 2007. Phases of Product Development. Office of Research and Development, Pharmaceutical Manufacturers Association.
142. Wiseman, G. A., E. Kornmehl, B. Leigh, W. D. Erwin, D. A. Podoloff, S. Spies, R. B. Sparks, M. G. Stabin, T. Witzig, and C. A. White. 2003. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's Lymphoma. J Nucl Med 44:465-474.
143. Witzig, T. E., L. I. Gordon, F. Cabanillas, M. S. Czuczman, C. Emmanouilides, R. Joyce, B. L. Pohlman, N. L. Bartlett, G. A. Wiseman, N. Padre, A. J. Grillo-Lopez, P. Multani, and C. A. White. 2002. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463.
144. Zalutsky, M. R. 2003. Radionuclide therapy. Pp 315-348 in Handbook of Nuclear Chemistry Volume 4: Radiochemistry and Radiopharmaceutical Chemistry in Life Sciences. Roesch, F., ed. Dordrecht, Netherlands: Kluwer Academic.
145. Zasadny, K. R., and R. L. Wahl. 1993. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 189:846-850.
146. Zipursky, R. B., J. H. Meyer, and N. P. Verhoeff. 2007. PET and SPECT imaging in psychiatric disorders. Can J Psychiatry 52:146-157.